Advancements and regulations of biomanufacturing cell-based cartilage repair therapies

Jia Qian Tor; Quang Bach Le; Hariharan Ezhilarasu; Weng Wan Chan; Deepak Choudhury

doi:10.1016/j.tibtech.2024.09.016

Advancements and regulations of biomanufacturing cell-based cartilage repair therapies

Trends Biotechnol. 2024 Oct 10:S0167-7799(24)00277-4. doi: 10.1016/j.tibtech.2024.09.016. Online ahead of print.

Authors

Jia Qian Tor¹, Quang Bach Le², Hariharan Ezhilarasu¹, Weng Wan Chan¹, Deepak Choudhury³

Affiliations

¹ Biomanufacturing Technology, Bioprocessing Technology Institute (BTI), Agency for Science, Technology, and Research (A*STAR), 20 Biopolis Way, Singapore 138668.
² Biomanufacturing Technology, Bioprocessing Technology Institute (BTI), Agency for Science, Technology, and Research (A*STAR), 20 Biopolis Way, Singapore 138668. Electronic address: [email protected].
³ Biomanufacturing Technology, Bioprocessing Technology Institute (BTI), Agency for Science, Technology, and Research (A*STAR), 20 Biopolis Way, Singapore 138668. Electronic address: [email protected].

PMID: 39393937
DOI: 10.1016/j.tibtech.2024.09.016

Abstract

Cell-based therapies for cartilage repair, including autologous chondrocyte implantation and allogeneic stem cell treatments, show great promise but face challenges due to high costs and regulatory hurdles. This review summarizes available and investigational products, focusing on allogeneic therapies and the impact of diverse regulatory landscapes on their clinical translation.

Keywords: ACI; MSC; cartilage repair; cell therapy; clinical trial; regulatory.